

AUTHOR DECLARATION

We wish to draw the attention of the Editor to the following facts-whichfi may be considered as potential conflicts of interest and to significant financial contributions to this work.

Drs. Colrain, Bogan, Becker, Farid-Moayer, R. Goldberg and Lankford were funded by research grants from ApniCure to conduct the trial. Drs. A. Goldberg and Malhotra have received funding from ApniCure as research consultants. Dr. Siegel is the Chief Medical Officer of ApniCure. Dr. Black is a consultant to ApniCure and also an equity holder in the company.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from (ian.colrain@sri.com)

Signed by all authors as follows:

Ian M. Colrain		Mehran Farid-Moayer	_____
Jed Black		Rochelle Goldberg	_____
Lawrence C. Siegel		D. Alan Lankford	_____
Richard K. Bogan	_____	Andrew N. Goldberg	_____
Philip M. Becker	_____	Atul Malhotra	_____

AUTHOR DECLARATION

We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this work.

Drs. Colrain, Bogan, Becker, Farid-Moayer, R. Goldberg and Lankford were funded by research grants from ApniCure to conduct the trial. Drs. A. Goldberg and Malhotra have received funding from ApniCure as research consultants. Dr. Siegel is the Chief Medical Officer of ApniCure. Dr. Black is a consultant to ApniCure and also an equity holder in the company.


We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from (ian.colrain@sri.com)

Signed by all authors as follows:

Ian M. Colrain	_____	Mehran Farid-Moayer	_____
Jed Black	_____	Rochelle Goldberg	_____
Lawrence C. Siegel	_____	D. Alan Lankford	_____
Richard K. Bogan		Andrew N. Goldberg	_____
Philip M. Becker	_____	Atul Malhotra	_____

AUTHOR DECLARATION

We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this work.

Drs. Colrain, Bogan, Becker, Farid-Moayer, R. Goldberg and Lankford were funded by research grants from ApniCure to conduct the trial. Drs. A. Goldberg and Malhotra have received funding from ApniCure as research consultants. Dr. Siegel is the Chief Medical Officer of ApniCure. Dr. Black is a consultant to ApniCure and also an equity holder in the company.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from (ian.colrain@sri.com)

Signed by all authors as follows:

Ian M. Colrain _____

Mehran Farid-Moayer _____

Jed Black _____

Rochelle Goldberg _____

Lawrence C. Siegel _____

D. Alan Lankford _____

Richard K. Bogan _____

Andrew N. Goldberg _____

Philip M. Becker

Philip M. Becker

10/30/12

Atul Malhotra _____

AUTHOR DECLARATION

We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this work.

Drs. Colrain, Bogan, Becker, Farid-Moayer, R. Goldberg and Lankford were funded by research grants from ApniCure to conduct the trial. Drs. A. Goldberg and Malhotra have received funding from ApniCure as research consultants. Dr. Siegel is the Chief Medical Officer of ApniCure. Dr. Black is a consultant to ApniCure and also an equity holder in the company.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from (ian.colrain@sri.com)

Signed by all authors as follows:

Ian M. Colrain _____

Mehran Farid-Moayer _____

Jed Black _____

Rochelle Goldberg _____

Lawrence C. Siegel _____


D. Alan Lankford _____

Richard K. Bogan _____

Andrew N. Goldberg _____

Phillip M. Becker _____

Atul Malhotra _____



AUTHOR DECLARATION

We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this work.

Drs. Colrain, Bogan, Becker, Farid-Moayer, R. Goldberg and Lankford were funded by research grants from ApniCure to conduct the trial. Drs. A. Goldberg and Malhotra have received funding from ApniCure as research consultants. Dr. Siegel is the Chief Medical Officer of ApniCure. Dr. Black is a consultant to ApniCure and also an equity holder in the company.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from (ian.colrain@sri.com)

Signed by all authors as follows:

Ian M. Colrain	_____	Mehran Farid-Moayer	<u> <i>M. Farid</i> </u>
Jed Black	_____	Rochelle Goldberg	_____
Lawrence C. Siegel	_____	D. Alan Lankford	_____
Richard K. Bogan	_____	Andrew N. Goldberg	_____
Philip M. Becker	_____	Atul Malhotra	_____

AUTHOR DECLARATION

We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this work.

Drs. Colrain, Bogan, Becker, Farid-Moayer, R. Goldberg and Lankford were funded by research grants from ApniCure to conduct the trial. Drs. A. Goldberg and Malhotra have received funding from ApniCure as research consultants. Dr. Siegel is the Chief Medical Officer of ApniCure. Dr. Black is a consultant to ApniCure and also an equity holder in the company.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from (ian.colrain@sri.com)

Signed by all authors as follows:

Ian M. Colrain _____

Mehran Farid-Moayer _____

Jed Black _____

Rochelle Goldberg _____

Lawrence C. Siegel _____

D. Alan Lankford 

Richard K. Bogan _____

Andrew N. Goldberg _____

Philip M. Becker _____

Atul Malhotra _____

AUTHOR DECLARATION

We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this work.

Drs. Colrain, Bogan, Becker, Farid-Moayer, R. Goldberg and Lankford were funded by research grants from ApniCure to conduct the trial. Drs. A. Goldberg and Malhotra have received funding from ApniCure as research consultants. Dr. Siegel is the Chief Medical Officer of ApniCure. Dr. Black is a consultant to ApniCure and also an equity holder in the company.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from (ian.colrain@sri.com)

Signed by all authors as follows:

Ian M. Colrain _____

Mehran Farid-Moayer _____

Jed Black _____

Rochelle Goldberg _____

Lawrence C. Siegel _____


D. Alan Lankford _____

Richard K. Bogan _____

Andrew N. Goldberg _____

Philip M. Becker _____

Atul Malhotra _____



AUTHOR DECLARATION

We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this work.

Drs. Colrain, Bogan, Becker, Farid-Moayer, R. Goldberg and Lankford were funded by research grants from ApniCure to conduct the trial. Dr. Malhotra has received funding from ApniCure as a research consultant. Dr. Siegel is the Chief Medical Officer of ApniCure. Drs. Black and A. Goldberg are consultants to ApniCure and also equity holders in the company.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from (ian.colrain@sri.com)

Signed by all authors as follows:

Ian M. Colrain _____

Mehran Farid-Moayer _____

Jed Black _____

Rochelle Goldberg _____

Lawrence C. Siegel _____


D. Alan Lankford _____

Richard K. Bogan _____

Andrew N. Goldberg _____

Philip M. Becker _____

Atul Malhotra _____



650 8592743

AUTHOR DECLARATION

We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest and to significant financial contributions to this work.

Drs. Colrain, Bogan, Becker, Farid-Moayer, R. Goldberg and Lankford were funded by research grants from ApniCure to conduct the trial. Drs. A. Goldberg and Malhotra have received funding from ApniCure as research consultants. Dr. Siegel is the Chief Medical Officer of ApniCure. Dr. Black is a consultant to ApniCure and also an equity holder in the company.

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from (ian.colrain@sri.com)

Signed by all authors as follows:

Ian M. Colrain _____

Mehran Farid-Moayer _____

Jed Black _____

Rochelle Goldberg _____

Lawrence C. Siegel _____

D. Alan Lankford _____

Richard K. Bogan _____

Andrew N. Goldberg _____

Philip M. Becker _____

Atul Malhotra 